RESEARCH MONOGRAPH · KDC-MN-290

Thyrotropin-Releasing Hormone (TRH)

May 9, 2026 Kodiac biolabs Research Revised May 30, 2026 3 min read

Our opinion on this compound

75/100

Tiny tripeptide with effects way beyond thyroid signaling, slept-on as a CNS research tool

TRH is one of the more interesting endocrine peptides because the name dramatically undersells what the molecule does. Yes, it's the hypothalamic tripeptide (pGlu-His-Pro-NH2) that triggers TSH release from the anterior pituitary, that's the textbook story. But the central nervous system effects of TRH are honestly the more interesting biology, and the research literature has been quietly accumulating for forty years.

The peripheral story is what gets it into pharmacology textbooks. TRH binds TRH-R1 on thyrotrophs, triggers TSH release, downstream T4/T3 secretion. The TRH stimulation test was the gold standard for pituitary thyroid axis evaluation for decades before sensitive TSH assays mostly replaced it. Mechanism is well-mapped.

The CNS biology is where it gets interesting. TRH is broadly distributed in the brain (way beyond the hypothalamus), it has clear arousal/vigilance effects, it modulates mood and appetite in animal models in ways that are not explained by downstream thyroid effects, and there's a body of work on TRH analogs (taltirelin, montirelin, etc.) for neurodegenerative indications. The TRH-R2 receptor in the CNS does different things than TRH-R1 in the pituitary and the dual-receptor story is still being unpacked.

What we like: small, well-characterized peptide with a tight mechanism on the endocrine side and a much messier (in the interesting way) CNS pharmacology. The clinical TRH stimulation test data is enormous and the dose-response is well-mapped.

What we dont love is that TRH itself is pharmacokinetically annoying. Plasma half-life is about 5 minutes, oral bioavailability is essentially zero, and the CNS penetration is poor without analog modification. So most of the CNS work has happened on TRH analogs, not TRH proper, which makes the parent peptide a less practical research tool for CNS questions than people initially hope.

Sourcing is fine. TRH is a 3-residue peptide with a pyroglutamyl N-terminus and a C-terminal amide, both well-understood synthetic challenges. Research-grade material is consistent and HPLC purity is easy to verify.

Honestly, TRH is one of those compounds where if you're working on hypothalamic-pituitary axis questions it's a reference tool, and if you're working on CNS effects it's a starting point that pushes you toward the analog literature pretty quickly.

Evidence: 75
Mechanism: 85
Reliability: 75
Safety: 75
Sourcing: 80
Value: 70
Signal: 70
Staying power: 70

Plain-language summary Intrigue 55 / 100

Thyrotropin-releasing hormone (TRH) is the smallest peptide hormone in the hypothalamic-pituitary system, just three amino acids. Its job is to trigger TSH release from the pituitary, which then drives the thyroid gland. TRH was independently isolated by Schally and Guillemin in the late 1960s, work that won the 1977 Nobel Prize. Clinically it has been used as a probe for pituitary function (the TRH stimulation test), now largely replaced by sensitive TSH assays. Beyond thyroid, TRH receptors are scattered through the brain and TRH itself produces arousal, mood-elevating, and cognitive effects in research, leading to investigation in depression, ALS, and cognitive impairment, with no major clinical wins. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Hypothalamic tripeptide (thyrotropin-releasing hormone)

A hypothalamic tripeptide that triggers pituitary TSH release; used as a pharmacological probe for pituitary function and investigated for cognitive enhancement.

Abstract

TRH (thyrotropin-releasing hormone; pyroglutamyl-histidyl-prolinamide; CAS 24305-27-9; molecular formula C16H22N6O4; molecular weight 362.39) is a hypothalamic tripeptide that activates pituitary TRH receptors to trigger TSH release. Discovered independently by Schally and Guillemin in the late 1960s (Nobel Prize 1977). The compound is the smallest peptide hormone of the hypothalamic-pituitary axis. Pharmacologically, exogenous TRH has been used as a clinical probe of pituitary thyrotroph function (the TRH stimulation test, now largely supplanted by sensitive TSH assays). Beyond TSH release, TRH receptors are distributed throughout the CNS and TRH has direct effects on arousal, mood, and cognitive function; clinical trials in depression, ALS, and spinocerebellar ataxia have been mixed. Plasma half-life is approximately 5 minutes, severely limiting clinical use; analog development has produced taltirelin (approved in Japan for spinocerebellar degeneration) and other TRH receptor agonists with extended pharmacokinetics. Used as the canonical hypothalamic peptide for pituitary axis research.

Mechanism of action

Tripeptide TRH receptor agonist; triggers pituitary TSH release. Direct CNS effects on arousal, mood, and cognition through widely distributed TRH receptors.

Reported research dose ranges

Research 200 to 500 mcg intravenous (TSH stimulation test); intranasal research applications 1 to 5 mg.

References

Reichlin S. Neuroendocrinology of TRH. N Engl J Med 1989.
Gary KA, et al. The thyrotropin-releasing hormone (TRH) hypothesis of homeostatic regulation. CNS Spectr 2003.
Yarbrough GG, et al. Thyrotropin-releasing hormone: structure-activity relationships. CNS Drug Rev 2007.

Read the full monograph

The full reference document is available as a research-use-only PDF download. Note: PDFs for newly added compounds may take a few hours to propagate after this article was published.

KDC-MN-290

The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

Thyrotropin-Releasing Hormone (TRH)

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs